title: Management of the patient with left ventricular hypertrophy.
abstract: The management of left ventricular hypertrophy (LVH) presupposes that the patient is identified by echocardiography and is carefully evaluated for risk stratification, taking into consideration possible associated complications. The role of non-pharmacological treatment is limited, except in obese patients. Drug treatment, especially using calcium antagonists, angiotensin converting enzyme inhibitors and beta-blockers, has proved to be effective in reducing LVH. These drugs are also effective in controlling, if not reversing, the associated pathophysiological changes and complications, such as impaired systolic and diastolic function, and ventricular arrhythmias. There is, however, no evidence of any beneficial effect on myocardial ischaemia. The desirable goal is LVH regression, but it may not be achievable in over 50% of patients, and it is not possible to identify patients in whom regression is likely. Regression, or control of each sequelae, could prevent sudden death, the evolution of hypertensive heart disease leading to heart failure and, probably, myocardial infarction. Patients must be followed carefully during and, particularly, at the beginning of the antihypertensive therapy which has to be gradually introduced. At best, blood pressure must be reduced while avoiding hypotension. The strategy of antihypertensive treatment has to be reconsidered on the basis of the presence of LVH and could lead to decreased cardiovascular morbidity and mortality of patients with LVH.
authors.affiliation: Clinical Methodology-Cardioangiology Unit, Second Medical School, Federico II, University of Naples, Italy.
authors.forename: O
authors.initials: O
authors.lastname: de Divitiis
authors.forename: A
authors.initials: A
authors.lastname: Celentano
authors.forename: G
authors.initials: G
authors.lastname: De Simone
authors.forename: S
authors.initials: S
authors.lastname: Di Somma
authors.forename: M
authors.initials: M
authors.lastname: Galderisi
authors.forename: V
authors.initials: V
authors.lastname: Liguori
authors.forename: M
authors.initials: M
authors.lastname: de Divitiis
authors.forename: M
authors.initials: M
authors.lastname: Petitto
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D005117:Cardiac Complexes, Premature / Q000503:physiopathology / Q000628:therapy; D003131:Combined Modality Therapy; D004562:Electrocardiography / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000503:physiopathology / Q000628:therapy*; D017379:Hypertrophy, Left Ventricular / Q000503:physiopathology / Q000628:therapy*
chemical_list: D000959:Antihypertensive Agents